Navigation Links
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Date:3/4/2008

XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer

indication

SEATTLE, March 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of patients with non-small cell lung cancer (NSCLC) who have ECOG (Eastern Cooperative Oncology Group) performance status 2 (PS2). The application is based on a positive opinion CTI received from the EMEA's Scientific Advice Working Party, which agreed to review the application based on the existing results of the phase III clinical trials of XYOTAX, known as the STELLAR trials.

In the STELLAR 4 trial, single-agent XYOTAX resulted in comparable survival to gemcitabine or vinorelbine in first-line patients and, with the exception of neuropathy known to be associated with taxane therapy, demonstrated significant reduction in several clinically meaningful toxicities, such as severe neutropenia and infection, and in the requirement for transfusions and use of hematopoietic growth factor support. In addition to improved tolerability, XYOTAX offered more convenient administration compared to currently used treatments and a reduction in overall utilization of medical resources compared to gemcitabine or vinorelbine.

The application will be formally reviewed for validation by the end of March. Upon validation, the marketing approval review process begins, which generally takes 15 to 18 months.

"This is an important milestone for CTI and demonstrates our commitment to bring XYOTAX to this underserved group of patients. Currently there are no approved treatments for first-line use in PS2 patients with non-small cell lung cancer. Every day counts when treating patients who may have an average life expectancy of only six months, so quality of life an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
10. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
11. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...ase of Test Development Program, ORANGE COUNTY, C...oulter, Inc. (NYSE: BEC ) announced today that it...bligation to Nephromics LLC, a Chestnut Hill,Mass...ense is for tests,related to the detection, monito...g cause of maternal death. In addition, Beckman Co...
(Date:8/18/2008)...re-FirstCall/ -- Micromet, Inc.,(Nasdaq: MITI ), ...rietary,antibodies for the treatment of cancer, in...bcast and conference call this morning, Monday,Au...m. Central European,Time) to discuss the blinatumo...E on August 15, 2008., To access the webcast and ...
(Date:8/14/2008)...irstCall/ -- AstraZeneca (NYSE: AZN ),today annou...al Cancer,Centre Singapore (NCCS) and the National...compounds. The collaboration, which is spelt out i...ned today, aims to further,build AstraZeneca,s dru...speed up access to new medicines of potential bene...
(Date:8/14/2008)...TE) showing clinical benefit in cancer,patients; B...ize and attack cancer...all/ -- Micromet, Inc.,(Nasdaq: MITI ), a biophar...ntibodies for the treatment of cancer, inflammatio...tion of a Phase 1 clinical study(1) on its,BiTE(R)...
Breaking Medicine Technology:Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 2Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 2AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 3AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 4AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 5AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds 6Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 2Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 3Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 4Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 5Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab 6HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 1HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 11176 2Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 1Oncology Metrics Launches the National Practice Benchmark 3A One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operat 11172 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 1Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 2Netsmart Technologies Extends Relationship with Manatee Glens for Enterprise Behavioral Health Software Solutions 3079 3Massive American Red Cross Tornado Relief Effort Spans Five States 11169 1Massive American Red Cross Tornado Relief Effort Spans Five States 11169 2
...s large multi-site lab faced challenges with manua...agement challenges which were exacerbated by staf...ized that better document control was essential fo...r laboratorians to more efficiently access and man...f Quality Management software packages and evaluat...
...Editor ,According to the American Diabetes Ass...es in 2002 was estimated to be $132 billion, or on... United States. A chronic disease with no cure, di...ype 2, and gestational) marked by high levels of b...duction, insulin action, or both. Nearly 20 millio...
Other Medicine Technology:Choosing Lab Quality Management Software 2Choosing Lab Quality Management Software 3Choosing Lab Quality Management Software 4Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 2Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control 3
(Date:8/20/2008)...Newswire/ -- The National Alliance on,Mental Illne...tes on mental,health services and invites the publ...rding it to others., The survey is available at ...udes a version in Spanish., In 2006, NAMI,s "Grad...hcare System for Serious Mental Illnesses" (http:...
(Date:8/20/2008)... calorie-burning brown fat can be produced experim...ses the prospect of new ways to fight obesity and ... Institute. , Reporting in the Aug. 21 issue of ... that brown fat, which is known as the "good" form... releases energy, unlike "bad" white fat that simp...
(Date:8/20/2008)...rth is part of a new generation of neurosurgeons w...ts. , At Loyola University Hospital, Duckworth i... to repair life-threatening aneurysms and to drama...Rather than removing large sections of the skull o...ch smaller openings. And in certain cases, he goes...
(Date:8/20/2008)...rn calories, hints of new ways to treat obesity ,...- A protein that induces bone growth also helps pr...urn calories and plays a role in fighting obesity,... Boston. , They said their finding about the pr...prevent and treat obesity. , The two main types...
Breaking Medicine News(10 mins):Health News:Grading the States; Mental Health Services Survey 2Health News:Making 'good' fat from muscle and vice versa 2Health News:Making 'good' fat from muscle and vice versa 3Health News:Brain surgery is getting easier on patients 2Health News:Brain surgery is getting easier on patients 3Health News:Bone Growth Protein Also Promotes 'Good' Fat 2
...a, high blood pressure or depression are more like...earchers at the University of Texas,// have survey...ars of age. They found that the partners of those ... per cent more likely to have these problems thems...
... could soon be procurable in the doctor's office o...drug responses. Researchers at LGC// (Laboratory o...duce a DNA test kit which uses saliva, blood or ur...n 15 to 20 minutes. The device has been made smal...
...f Texas feel that they may have found an effective...hat threatens clear vision.// Using photodynamic t...n three patients who were suffering from intraocul...ed serious retinal detachments. Intraocular choroi...
... observed that nearly one out of every five medica...s may be in error. The problem occurs regardless o...e nation's leading health care accrediting organiz...ne released a report titled, "To Err is Human: Bui...
Other Medicine News:
... care., ,S/5 Anesthesia Delivery Unit (ADU) is an...rt of the S/5 Anesthesia System, it combines enhan...d gas delivery and agent vaporization with patient... truly integrated system. The S/5 ADUs electronic ...
Tegagel hydrogel wound filler and Tegagel hydrogel wound filler with gauze are amorphous hydrogel dressings specially formulated to help provide a moist environment that has been shown to enhance wou
...rence card system as well as a perpetual inventory...equirements of the surgical services department. T...ray of inventory management capabilities enables t... charge capture workflow. Regardless of how suppli...
Easy to Use manual vacuum system features a pumping mechanism that can be operated with one hand.
Medicine Products: